2023
High perceived stress in patients on opioid agonist therapies during rapid transitional response to the COVID-19 pandemic in Ukraine
Galvez S, Altice F, Meteliuk A, Ivasiy R, Machavariani E, Farnum S, Fomenko T, Islam Z, Madden L. High perceived stress in patients on opioid agonist therapies during rapid transitional response to the COVID-19 pandemic in Ukraine. Frontiers In Public Health 2023, 11: 1231581. PMID: 38098837, PMCID: PMC10720365, DOI: 10.3389/fpubh.2023.1231581.Peer-Reviewed Original ResearchConceptsOpioid agonist therapyOpioid use disorderAgonist therapyOAT patientsCOVID-19 pandemicSubstance useTake-home dosingAdditional psychosocial supportHigher perceived stressHigh riskPerceived Stress ScalePsychiatric disordersUse disordersPatientsPatient stressPsychosocial supportCertain subgroupsSevere levelsHigh levelsHealthcare deliveryStress ScalePerceived stressTherapyExtraordinary high levelsDisordersAligning public health and public safety: Probation as a touchpoint to identify and link patients with opioid use disorder to opioid agonist treatment
Bromberg D, Galvez de Leon S, Litz T, Azbel L, Liberman A, Polonsky M, Dvoriak S, Saichuk N, Taxman F, Altice F. Aligning public health and public safety: Probation as a touchpoint to identify and link patients with opioid use disorder to opioid agonist treatment. PLOS Global Public Health 2023, 3: e0002349. PMID: 37910486, PMCID: PMC10619786, DOI: 10.1371/journal.pgph.0002349.Peer-Reviewed Original ResearchCriminal justice settingsOpioid use disorderBrief interventionUse disordersPrevalence of OUDProbation centersHIV prevention effortsJustice settingsMental healthHigh rateCommunity supervision settingsOAT servicesSBIRT interventionAgonist therapyHIV testingOpioid dependenceAgonist treatmentConsecutive individualsTreatment strategiesGeneral populationProbationSBIRTPrevention effortsSupervision settingParticipantsPreferences in medications for patients seeking treatment for opioid use disorder: A conjoint analysis
Muthulingam D, Hassett T, Madden L, Bromberg D, Fraenkel L, Altice F. Preferences in medications for patients seeking treatment for opioid use disorder: A conjoint analysis. Journal Of Substance Use And Addiction Treatment 2023, 154: 209138. PMID: 37544510, DOI: 10.1016/j.josat.2023.209138.Peer-Reviewed Original ResearchConceptsOpioid use disorderRoute of administrationPatient preferencesUse disordersSymptom reliefTreatment preferencesSide effectsCross-sectional observational studyTreatment-seeking peopleChi-squared analysisOral medicationsPublic health crisisOUD treatmentTreatment uptakeWithdrawal symptomsOpioid epidemicObservational studyTreatment decisionsSTROBE checklistSustainability of treatmentPatientsMedicationsHealth professionalsUtility scoresLarger studyImproving HIV and HCV Testing in Substance Use Disorder Programs (SUDs) That Provide Medications for Opiate Use Disorder (MOUD): Role of Addressing Barriers and Implementing Universal and Site-Specific Approaches
Brooks R, Wegener M, Freeman B, Fowles C, Madden L, Tetrault J, Nichols L, Altice F, Villanueva M. Improving HIV and HCV Testing in Substance Use Disorder Programs (SUDs) That Provide Medications for Opiate Use Disorder (MOUD): Role of Addressing Barriers and Implementing Universal and Site-Specific Approaches. Health Promotion Practice 2023, 24: 1018-1028. PMID: 37439759, DOI: 10.1177/15248399231169791.Peer-Reviewed Original ResearchConceptsHIV/HCV coinfectionSubstance use disorder programsHCV testingOpiate use disorderHCV coinfectionUse disordersNominal group techniqueSubstance use disorder treatment centersCascade of careRates of HIVDisorder treatment centersQuality improvement effortsRate of testingHCV acquisitionHCV cureImproving HIVSUD clinicsHepatitis CHIV testingPrior diagnosisSubsequent referralReferral ratesHIV epidemicHIVTreatment centersLeveraging existing provider networks in Europe to eliminate barriers to accessing opioid agonist maintenance therapies for Ukrainian refugees
Nikitin B, Bromberg D, Madden L, Stöver H, Teltzrow R, Altice F. Leveraging existing provider networks in Europe to eliminate barriers to accessing opioid agonist maintenance therapies for Ukrainian refugees. PLOS Global Public Health 2023, 3: e0002168. PMID: 37440470, PMCID: PMC10343058, DOI: 10.1371/journal.pgph.0002168.Peer-Reviewed Original ResearchOpioid use disorderAgonist maintenance therapyMaintenance therapyInjection drug usePrevention of HIVGold standard treatmentRisk of HIVHigh prevalence ratesCare continuityStandard treatmentPrevalence ratesUse disordersImplementation science lensDrug useHarm reductionTreatment modelHIVPatientsClinicTherapyAddiction treatment modelsTreatmentProvidersInvasionInterview participants
2022
The Initial Response to COVID-19 Disruptions for Older People with HIV in Ukraine
Rozanova J, Rich K, Altice F, Shenoi S, Zaviryukha I, Kiriazova T, Mamedova E, Shipunov O, Yariy V, Deac A, Zeziulin O. The Initial Response to COVID-19 Disruptions for Older People with HIV in Ukraine. Geriatrics 2022, 7: 138. PMID: 36547274, PMCID: PMC9777936, DOI: 10.3390/geriatrics7060138.Peer-Reviewed Original ResearchGeneralised anxiety disorderSymptoms of depressionSymptoms of anxietyHIV treatmentSevere depressionOlder peopleMental healthActive drug useSubstance use disordersFirth logistic regression modelHigher suicidal ideationLogistic regression modelsIndependent correlatesUse disordersTelehealth strategiesDrug useSuicidal ideationSymptomsHIVAnxiety disordersSubstance useDepressionStandardised scalesCOVID-19 restrictionsInitial responseImpact of prerelease methadone on mortality among people with HIV and opioid use disorder after prison release: results from a randomized and participant choice open-label trial in Malaysia
Bazazi A, Culbert G, Wegman M, Heimer R, Kamarulzaman A, Altice F. Impact of prerelease methadone on mortality among people with HIV and opioid use disorder after prison release: results from a randomized and participant choice open-label trial in Malaysia. BMC Infectious Diseases 2022, 22: 837. PMID: 36368939, PMCID: PMC9652918, DOI: 10.1186/s12879-022-07804-6.Peer-Reviewed Original ResearchConceptsOpioid use disorderOpioid agonist therapyInfectious etiologyMost deathsUse disordersSample of menPrison releaseOpen-label trialT-lymphocyte countsPredictors of mortalityNational death recordsCrude mortality rateProportional hazards modelCovariate-adjusted modelsLow CD4Methadone initiationModified intentionAgonist therapySurvival benefitTreat analysisMethodsThis studyHIVHazards modelMortality rateMethadonePreliminary analysis of self-reported quality health indicators of patients on opioid agonist therapy at specialty and primary care clinics in Ukraine: A randomized control trial
Pashchenko O, Bromberg D, Dumchev K, LaMonaca K, Pykalo I, Filippovych M, Esserman D, Polonsky M, de Leon S, Morozova O, Dvoriak S, Altice F. Preliminary analysis of self-reported quality health indicators of patients on opioid agonist therapy at specialty and primary care clinics in Ukraine: A randomized control trial. PLOS Global Public Health 2022, 2: e0000344. PMID: 36962514, PMCID: PMC10021202, DOI: 10.1371/journal.pgph.0000344.Peer-Reviewed Original ResearchPrimary care clinicsOpioid use disorderOpioid agonist therapyPrimary careComplete self-reported dataPatient medical record dataMedical record dataComprehensive health outcomesAddiction treatment clinicsAdult PWIDAgonist therapySecondary outcomesParent trialPrimary outcomeRandomized participantsCare clinicsTreatment clinicsIntervention sitesUse disordersHealth outcomesAddiction treatmentRecord dataSelf-reported dataHealth indicatorsClinicUsing nominal group technique to identify barriers and facilitators to preventing HIV using combination same-day pre-exposure prophylaxis and medications for opioid use disorder
Eger WH, Altice FL, Lee J, Vlahov D, Khati A, Osborne S, Wickersham JA, Bohonnon T, Powell L, Shrestha R. Using nominal group technique to identify barriers and facilitators to preventing HIV using combination same-day pre-exposure prophylaxis and medications for opioid use disorder. Harm Reduction Journal 2022, 19: 120. PMID: 36307817, PMCID: PMC9616614, DOI: 10.1186/s12954-022-00703-8.Peer-Reviewed Original ResearchConceptsSame-day prescriptionPre-exposure prophylaxisOpioid use disorderHIV transmissionUse disordersClinical stakeholdersAvailability of providersSystems of careHealth care systemCoordinated careNew practice modelClinical careMedicationsPharmacy deliveryMOUDNominal group techniqueLocal prescribersPWIDSexual riskPrEPCare systemHealth benefitsCareMultiple visitsProphylaxisStrengthening systems of care for people with or at risk for HIV, HCV and opioid use disorder: a call for enhanced data collection
Eller AJ, DiDomizio EE, Madden LM, Oliva JD, Altice FL, Johnson KA. Strengthening systems of care for people with or at risk for HIV, HCV and opioid use disorder: a call for enhanced data collection. Annals Of Medicine 2022, 54: 1714-1724. PMID: 35775786, PMCID: PMC9377256, DOI: 10.1080/07853890.2022.2084154.Peer-Reviewed Original ResearchConceptsCascade of careHuman immunodeficiency virusOpioid use disorderHepatitis C virusPublic health planningUse disordersCo-occurring opioid use disorderHealth planningBurden of diseaseSystems of careQuality improvement activitiesOUD cascadeTreatment initiationImmunodeficiency virusC virusPatient outcomesTreatment accessPayer sourceTreatment retentionHealth systemHealthcare systemCareSyndemicDisordersVirusPregnant Women and Opioid Use Disorder: Examining the Legal Landscape for Controlling Women's Reproductive Health.
Madden L, Oliva J, Eller A, DiDomizio E, Roosa M, Blanchard L, Kil N, Altice F, Johnson K. Pregnant Women and Opioid Use Disorder: Examining the Legal Landscape for Controlling Women's Reproductive Health. American Journal Of Law & Medicine 2022, 48: 209-222. PMID: 36715261, DOI: 10.1017/amj.2022.26.Peer-Reviewed Original ResearchConceptsOpioid use disorderReproductive healthPregnant womenUse disordersPregnant women's useEvidence-based treatmentsReproductive health outcomesWomen's reproductive healthIntersection of HIVSystems of careHealth care choicesPostpartum womenChild healthTreatment policyUnintentional pregnancyHealth outcomesLarger studyWomenTransactional sexCare choicesMinority womenOutcomesOUDWomen's useDisordersPrevalence and Correlates of Active Amphetamine-Type Stimulant Use Among Female Sex Workers in Malaysia
Pedersen CJ, Wickersham JA, Altice FL, Kamarulzaman A, Khoshnood K, Gibson BA, Khati A, Maviglia F, Shrestha R. Prevalence and Correlates of Active Amphetamine-Type Stimulant Use Among Female Sex Workers in Malaysia. Frontiers In Psychiatry 2022, 13: 879479. PMID: 35774093, PMCID: PMC9237260, DOI: 10.3389/fpsyt.2022.879479.Peer-Reviewed Original ResearchFemale sex workersATS useSubstance use disordersAmphetamine-type stimulantsUse disordersSevere substance use disordersAmphetamine-type stimulant useSex workersAdverse health outcomesLogistic regression analysisAdverse health consequencesSexual risk behaviorsBehavioral health issuesUse of drugsHarm reduction strategiesSex work clientsRespondent-driven samplingHIV transmissionMultivariable modelHigh prevalenceHealth outcomesDrug useSex workTransgender womenRisk behaviorsA pilot implementation study to scale-up methadone in incarcerated persons with opioid use disorder and retain them on treatment after release in Moldova
Dorgay CE, Bromberg DJ, Doltu S, Litz T, Galvez S, Polonsky M, Dvoryak S, Altice FL. A pilot implementation study to scale-up methadone in incarcerated persons with opioid use disorder and retain them on treatment after release in Moldova. International Journal Of Drug Policy 2022, 104: 103683. PMID: 35417790, PMCID: PMC9827420, DOI: 10.1016/j.drugpo.2022.103683.Peer-Reviewed Original ResearchConceptsMethadone maintenance treatmentOpioid use disorderUse disordersBrief interventionPilot implementation studySBIRT interventionTreatment initiationMaintenance treatmentMethadonePotential implementation strategiesIncarcerated personsInterventionImplementation studyTreatment proceduresBaselineDisordersTreatmentParticipantsDays of releaseReleaseImplementation strategiesPre-trial detention facilitySessionsHIVReferralViral Suppression Levels in Men Who Have Sex With Men and Transgender Women With Newly Diagnosed HIV and Alcohol Use Disorder in Peru: Results From a Randomized, Double-Blind, Placebo-Controlled Trial Using Oral Naltrexone
Gonzales P, Bachireddy C, Grieco A, Ding R, de Leon S, Ulrich A, Lama J, Duerr AC, Altice FL. Viral Suppression Levels in Men Who Have Sex With Men and Transgender Women With Newly Diagnosed HIV and Alcohol Use Disorder in Peru: Results From a Randomized, Double-Blind, Placebo-Controlled Trial Using Oral Naltrexone. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2022, 89: 462-471. PMID: 34897226, PMCID: PMC8881312, DOI: 10.1097/qai.0000000000002889.Peer-Reviewed Original ResearchConceptsMSM/transgender womenAlcohol use disorderOral naltrexoneTransgender womenViral suppressionUse disordersEFV/TDF/FTCTreatment of AUDMaximal viral suppressionSingle treatment regimenPlacebo-controlled trialTDF/FTCAntiretroviral therapy adherenceUse of naltrexoneEvidence-based treatmentsViral suppression levelsMVs levelsSecondary outcomesTherapy adherenceLow adherenceAdherence levelsNaltrexoneAUD treatmentHIVPlaceboThe development and initial validation of the Russian version of the BASIS-24
Madden L, Farnum S, Bromberg D, Barry D, Mazhnaya A, Fomenko T, Meteliuk A, Marcus R, Rozanova J, Poklad I, Dvoriak S, Altice F. The development and initial validation of the Russian version of the BASIS-24. Addiction Science & Clinical Practice 2022, 17: 65. PMID: 36435811, PMCID: PMC9701377, DOI: 10.1186/s13722-022-00343-0.Peer-Reviewed Original ResearchConceptsBASIS-24Addiction treatmentHIV prevention goalsSubset of patientsOpioid use disorderSymptom Identification ScaleMental health statusResultsCronbach’s alpha coefficientsMOUD patientsSeverity InstrumentTuberculosis epidemicEffective treatmentUse disordersHealth statusHealthcare professionalsMental healthPrevention goalsRelationships subscaleTreatment deliveryExploratory principal component analysisOpioidsHIVPatientsAlpha coefficientEECA region
2021
Treatment of Hepatitis C virus among people who inject drugs at a syringe service program during the COVID-19 response: The potential role of telehealth, medications for opioid use disorder and minimal demands on patients
Sivakumar A, Madden L, DiDomizio E, Eller A, Villanueva M, Altice FL. Treatment of Hepatitis C virus among people who inject drugs at a syringe service program during the COVID-19 response: The potential role of telehealth, medications for opioid use disorder and minimal demands on patients. International Journal Of Drug Policy 2021, 101: 103570. PMID: 34954493, PMCID: PMC8685180, DOI: 10.1016/j.drugpo.2021.103570.Peer-Reviewed Original ResearchConceptsOpioid use disorderHepatitis C virusSyringe services programDifferentiated care modelPerson visitsC virusCare modelUse disordersInitiation of DAAChronic HCV infectionEvidence-based treatmentsCOVID-19Initial phlebotomyVirological responseHCV infectionHCV treatmentAdditional patientsElevated riskPatientsClient-centred approachPWIDHIVPerson contactTreatment demandLaboratory screeningMethadone within prison and linkage to and retention in treatment upon community release for people with opioid use disorder in Kyrgyzstan: Evaluation of a national program
Bachireddy C, Shrestha R, Bromberg DJ, Azbel L, Kurmanalieva A, Wegman M, Shumskaya N, Rozanova J, Meyer JP, Altice FL. Methadone within prison and linkage to and retention in treatment upon community release for people with opioid use disorder in Kyrgyzstan: Evaluation of a national program. International Journal Of Drug Policy 2021, 101: 103558. PMID: 34915426, PMCID: PMC9998103, DOI: 10.1016/j.drugpo.2021.103558.Peer-Reviewed Original ResearchConceptsHIV statusMean treatment durationOpioid use disorderPositive HIV statusDuration of treatmentMethadone doseHIV incidenceMethadone servicesMethadone treatmentIndependent correlatesHIV preventionUse disordersTreatment durationMethadoneNational programTreatmentHIVAdministrative dataCommunity releaseMonthsKyrgyz prisonsFirst evaluationIncarcerated peopleDurationReleasePreference for and Efficacy of a PrEP Decision Aid for Women with Substance Use Disorders
Meyer J, Price C, Tracey D, Sharpless L, Song Y, Madden L, Elwyn G, Altice F. Preference for and Efficacy of a PrEP Decision Aid for Women with Substance Use Disorders. Patient Preference And Adherence 2021, 15: 1913-1927. PMID: 34511887, PMCID: PMC8420782, DOI: 10.2147/ppa.s315543.Peer-Reviewed Original ResearchSubstance use disordersPersonal HIV riskHIV preventionAddiction treatment servicesHIV riskUse disordersTreatment servicesPatient-centered decision aidAwareness of PrEPHIV prevention cascadeInitiation of PrEPPre-exposure prophylaxisOpioid use disorderStandard of careDecision aidAlcohol use severityHalf of participantsAddiction treatment programsDA participantsPrevention cascadePrimary outcomeIndependent correlatesHigh riskDecisional preferencesHigher alcohol use severityThe opioid crisis and HIV in the USA: deadly synergies
Hodder SL, Feinberg J, Strathdee SA, Shoptaw S, Altice FL, Ortenzio L, Beyrer C. The opioid crisis and HIV in the USA: deadly synergies. The Lancet 2021, 397: 1139-1150. PMID: 33617769, DOI: 10.1016/s0140-6736(21)00391-3.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAnalgesics, OpioidBlack or African AmericanCase-Control StudiesDisease OutbreaksEvidence-Based MedicineFemaleFentanylHealth Services AccessibilityHispanic or LatinoHIV InfectionsHumansMaleNeedle SharingOpiate OverdoseOpioid EpidemicOpioid-Related DisordersSocial StigmaUnited StatesWhite PeopleYoung AdultConceptsNew HIV diagnosesHIV diagnosisOpioid epidemicHIV preventionMultiple evidence-based interventionsGreat public health problemRecent HIV outbreaksOpioid overdose death ratesOpioid use disorderLarge central metropolitan areasPublic health problemOverdose death ratesComprehensive health careEvidence-based interventionsDeadly synergyHIV acquisitionSynthetic opioid fentanylSyringe sharingHIV outbreakUse disordersOpioid fentanylTreatment servicesHealth problemsOpioid crisisDeath rateChapter 9 Outpatient opioid use disorder treatment for the ID physician
Muthulingam D, Madden L, Altice F. Chapter 9 Outpatient opioid use disorder treatment for the ID physician. 2021, 161-187. DOI: 10.1016/b978-0-323-68328-9.00009-6.Peer-Reviewed Original ResearchOpioid use disorderOUD treatmentOpioid use disorder treatmentExtended-release naltrexoneInfectious disease cliniciansInitiation of treatmentSpecial clinical considerationsUse disorder treatmentHIV practiceID cliniciansOUD pharmacotherapyIntegrated care deliveryID physiciansMedication optionsOpioid epidemicTreatment expansionTreatment accessUse disordersAddiction specialistsClinical considerationsOUD managementDisorder treatmentGeneral IDCare deliveryPractice settings